Hotter inflation has pushed the Federal Reserve back toward rate increases, and the bond market is repricing around it. The Labor Department said consumer prices rose 0.4% in October, the third straight monthly gain of 0.4% or more and above the 0.3% that economists polled by Reuters had expected.
Stocks closed lower on November 10, the day the report came out, as the data hardened expectations for a December rate increase. Brent crude slipped below $90 a barrel for the first time since August.
Hot Inflation Puts the Fed Back on a Hiking Path
Federal Reserve Governor Christopher Waller said the central bank should raise short-term borrowing costs by at least 25 basis points in December. He spoke before the inflation report came out, and he added that a half-point increase deserves consideration if price pressures speed up.
Traders have taken the message on board. They now fully price a quarter-point increase at the December 9 meeting and see more than 80 basis points of tightening by September 2027, up from roughly 50 basis points before the October inflation data, Bloomberg reported. Readers weighing what that means for valuations can find more names in our ranking of affordable stocks Wall Street analysts like.
Treasury Yields Above 5% Change the Math for Stocks
The 10-year Treasury yield stood at about 5.14% on November 17 after October retail sales growth moderated. A resilient economy, heavy government and corporate bond sales, and worries about the federal deficit are adding to the pressure from inflation. By Bloomberg‘s count, it is on pace for its 27th close above 5% this year, against 29 in 2007. It peaked at 5.36% on October 7, its highest level in regular trading since 2002.
JPMorgan Asset Management portfolio manager Priya Misra said yields above 5% reflect a “risk premium due to uncertainty about the Fed.” Dan Carter, senior portfolio manager at Fort Washington Investment Advisors, said the risk and reward in fixed income looks better than it has in quite some time. Ian Lyngen, head of US rate strategy at BMO Capital Markets, said the higher rates have effectively frozen activity in real estate, and 30-year mortgage rates have stayed above 7% since mid-September.
Forecasters expect some relief, though not much. Morgan Stanley projects the 10-year yield at 5% at the end of 2027, and Goldman Sachs at 4.6%. We also covered oversold AI stocks where analysts see upside of 50% or more in a separate list. The Fed’s next decision comes on December 9.

Our Methodology
To compile this list, we reviewed analyst rating upgrades and coverage initiations announced on Wednesday, November 18, 2026. We have ranked these stocks in ascending order of their average upside potential, as of November 18.
At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).
10 Stocks Analysts Upgraded On Wednesday
10. CNX Resources (NYSE:CNX)
Average Upside Potential: 7%
Morgan Stanley upgraded CNX Resources to Equalweight from Underweight on November 18 and raised its price target to $36 from $34. That moves the stock from a negative view to a neutral one. The firm’s argument centers on hedging: CNX has about 80% of its 2027 production hedged, compared with an average of 37% across the companies Morgan Stanley covers, which should keep cash flow steadier if natural gas prices weaken.
CNX is a Pittsburgh-based natural gas producer that also owns midstream assets and sells pipeline-quality gas mainly to wholesalers. It describes itself as a low carbon intensity natural gas company. In the third quarter of 2026 it earned $1.12 per diluted share, down from the third quarter of 2025, and the shares slid afterward because management sounded cautious about 2027 production and Appalachian gas prices were weak.
The company did raise its full-year 2026 free cash flow guidance, to about $550 million. Protected prices on most of next year’s volumes are what tie that guidance to Morgan Stanley’s call: less of the cash flow is exposed if gas prices fall.
9. Manhattan Associates (NASDAQ:MANH)
Average Upside Potential: 11%
JPMorgan analyst Alexei Gogolev started coverage of Manhattan Associates on November 18 with an Overweight rating and a $308 price target. He sees a company early in its shift to cloud software, with only about a quarter of its installed base converted.
Manhattan Associates develops software that manages supply chains, inventory and omnichannel operations for retailers, wholesalers, manufacturers and logistics providers. JPMorgan’s reading is that the company is several years behind peers in moving customers to the cloud, so more of the growth is still ahead. The cloud version of the software is where the growth is showing up. In the third quarter of 2026, cloud revenue grew 28% and total revenue reached $306.2 million. Chief Executive Officer Eric Clark said the company posted another record bookings quarter on strong demand.
Valuation is where bears have an argument. The stock trades at 40.51 times forward earnings, while the company’s gross margin over the past 12 months was 55.35%. Gogolev’s case leans on the conversions still ahead: each customer that moves to the cloud adds to the recurring revenue base behind the faster growth rate.
8. ExxonMobil (NYSE:XOM)
Average Upside Potential: 14%
Erste Group analyst Hans Engel upgraded ExxonMobil to Buy from Hold on November 18, citing the company’s integrated model and balance sheet. No target was given.
ExxonMobil, headquartered in Spring, Texas, produces oil and natural gas, refines it into fuels, and makes chemicals and specialty products. In the third quarter of 2026 it reported adjusted earnings of $4.23 per share, up from $3.52 in the second quarter of 2026. Free cash flow was $19.1 billion, and the company announced $20 billion of share repurchases for 2027. It has also raised its annual dividend for 44 consecutive years. Chairman and Chief Executive Officer Darren Woods said the company is increasing production while improving efficiency, and ExxonMobil took over operatorship of the Papua LNG project in the third quarter of 2026 and agreed to raise its working interest in it.
Not every business improved. Adjusted earnings from chemical products fell to $725 million from $1.21 billion in the second quarter of 2026. Whether that unit can recover as its cost advantage narrows is the subject of our analysis of ExxonMobil’s chemical recovery.
7. Millicom International Cellular (NASDAQ:TIGO)
Average Upside Potential: 19%
JPMorgan analyst Marcelo Santos upgraded Millicom to Overweight from Neutral on November 18 and kept the price target at $105. The call followed a slide in the shares that began in mid-September.
Founded in 1990 and based in Luxembourg, Millicom sells mobile, home internet and cable television services under the Tigo brand across Latin America. In the third quarter of 2026, revenue rose 60.8% to $2.28 billion, though most of that came from acquisitions. Organic growth was 4.8%. The company generated equity free cash flow of $316 million in the third quarter of 2026.
Cash returns are part of the story. After its annual meeting, Millicom set a quarterly dividend of $0.75 per share, then raised its January and April 2027 payments. Chief Executive Officer Marcelo Benitez said the company is focusing in home internet on delivering greater value and a better experience rather than simply growing subscriber numbers, and that earthquakes in Colombia and Panama marked the third quarter of 2026. Our earlier piece on Millicom’s profit drop and record cash flow covers the cash flow side in more detail.
6. Elevance Health (NYSE:ELV)
Average Upside Potential: 19%
Argus upgraded Elevance Health to Buy from Hold on November 18 with a $510 price target, citing confidence in higher earnings growth in 2027. The company had reported results and raised its guidance on October 21.
Elevance Health sells health insurance, including Medicare Advantage and Medicaid plans. Its Health Benefits segment sells health plans to a range of customers. It also runs CarelonRx, a pharmacy benefit business, and Carelon Services, which provides care and health services to members and other customers. In the third quarter of 2026, operating revenue was $50.4 billion, and adjusted diluted earnings were $6.99 per share. The company said those results included a net non-operating benefit of $1.85 per share, so part of the third quarter’s earnings did not come from the insurance operations themselves.
The company then raised its full-year 2026 adjusted earnings guidance to at least $29.00 per share, and the release said results reflected improved operating performance. Analysts expect earnings per share to grow 4.01% next year, and Argus’s call rests on how much room it sees for earnings to grow in 2027 from that higher base.
5. Charles Schwab (NYSE:SCHW)
Average Upside Potential: 24%
Raymond James upgraded Charles Schwab to Strong Buy from Outperform on November 18 and set a $135 price target. The firm sees the brokerage benefiting from higher-for-longer interest rates through a wider net interest margin.
Schwab is a savings and loan holding company, with Investor Services and Advisor Services segments, that offers brokerage, banking, asset management and advice to individual investors and independent advisers. In the third quarter of 2026, it took in a record $190.4 billion of core net new assets, up 38% from the third quarter of 2025, and net revenues reached a record $7.2 billion, up from the third quarter of 2025. Investor Services covers retail brokerage, investment advisory, and banking and trust services for individual investors. The company reported those results on October 15. President and Chief Executive Officer Rick Wurster said clients opened 1.2 million new brokerage accounts in the third quarter of 2026.
Analysts expect earnings per share to grow 21.80% next year. Growth like that raises the question of how durable the franchise is, which we examined in our look at Schwab’s economic moat.
4. Camtek (NASDAQ:CAMT)
Average Upside Potential: 44%
Northland upgraded Camtek to Outperform from Market Perform on November 18 with a $130 price target. The firm pointed to comments on advanced packaging capacity from a major AI chip customer’s earnings call.
Camtek, based in Migdal HaEmek, Israel, makes inspection and metrology equipment that checks chips for defects during manufacturing, including the chips that go into AI systems. In the third quarter of 2026, revenue rose 28% to $161.3 million from $126.0 million in the third quarter of 2025, and non-GAAP earnings were $0.99 per diluted share. Its tools cover the front and mid-end of production up to the beginning of assembly. Chief Executive Officer Rafi Amit said that for the first time in the company’s history it has visibility a year ahead. The company expects revenue of about $180 million in the fourth quarter of 2026. It also gave an initial 2027 outlook of over $800 million.
Advanced packaging is the area Northland is betting on, and the company’s own 2027 outlook is the clearest sign of how much demand it expects there. Analysts expect earnings per share to grow 42.45% next year.
3. SOLV Energy (NASDAQ:MWH)
Average Upside Potential: 45%
UBS analyst Jon Windham upgraded SOLV Energy to Buy from Neutral on November 18, even as he cut the price target to $37 from $50. He argued the market is pricing in too little growth.
SOLV Energy, based in San Diego, designs, builds and maintains utility-scale solar and battery storage projects. In the third quarter of 2026, revenue rose 65% to $1.24 billion. Total backlog reached about $9.2 billion on September 30, 2026, and the company raised both its revenue and adjusted EBITDA guidance for full-year 2026. SOLV said it has more than 24 gigawatts under contract for operations and maintenance, and Chief Executive Officer George Hershman said the company delivered another quarter of strong results, citing execution and a focus on safety.
The stock has not followed the results. It has fallen back toward its IPO price of February 2026 despite acquisitions and rounds of raised guidance, and Windham’s lower target reflects that. UBS argues the market’s expectations for future earnings are too low given the size of the backlog. Margins are thin: the profit margin over the past 12 months was 3.25%.
2. Tandem Diabetes Care (NASDAQ:TNDM)
Average Upside Potential: 60%
Stifel analyst Jonathan Block upgraded Tandem Diabetes Care to Buy from Hold on November 18 and raised his price target to $26 from $22. He called the shares an attractive entry point near the low end of their trailing 12-month range and said channel checks suggest tubeless pumps will take share, which helps the company’s Mobi.
Tandem, based in San Diego, designs insulin pumps for people with diabetes, including the t:slim X2 and the smaller Mobi. In the third quarter of 2026, sales were $283.7 million, with about 33,000 pumps shipped. Gross margin rose 270 basis points from the third quarter of 2025 to 57%, and operating margin improved 830 basis points. Pharmacy-channel sales reached 15% of U.S. sales, part of a shift to a pay-as-you-go model that spreads out what customers pay.
Block also expects the company’s margin to keep improving, but he flagged risks too: competition from other pump makers, adoption of GLP-1 drugs, reimbursement cuts and regulatory hurdles for a patch pump. Tandem still lost money over the past 12 months, with an operating margin of -2.45%.
1. Innoviva (NASDAQ:INVA)
Average Upside Potential: 83%
Piper Sandler started coverage of Innoviva on November 18 with an Overweight rating and a $29 price target. The firm points to the company’s cash-generating hospital brands and royalty streams.
Innoviva describes itself as a diversified holding company. It collects royalties on once-daily inhaled respiratory medicines sold by GSK, including Relvar Breo Ellipta and Anoro Ellipta, and sells hospital drugs through Innoviva Specialty Therapeutics. In the third quarter of 2026, U.S. net product sales at that unit rose 45% to $43.3 million, and royalty revenue from GSK was $58.1 million. The company also bought back shares during the third quarter of 2026 and said it remains on track to meet its 2026 guidance of at least $150 million in U.S. net product sales.
Innoviva also holds strategic investments in other healthcare assets, which is why its reported results can swing with the value of those stakes. Our list of biotech stocks billionaires favor covers more of the industry. The commercial unit’s growth matters because royalty revenue has been flat to lower: GSK royalties were $63.4 million in the third quarter of 2025.
READ NEXT: ExxonMobil (XOM) Trades at a Premium Yet Earnings Are Expected to Shrink and Goldman Sachs (GS) vs Charles Schwab (SCHW): Which is a Better Stock to Buy?





